Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Patient reported toxicities: Development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy.
Authors
Sandra S. Shaw
Bonnie J. Addario Lung Cancer Foundation, Harleysville, PA
Sandra S. Shaw, Heather S.L. Jim, Sarah Eisel, Aasha Hoogland, David LeDuc, Adam P. Dicker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Patient-Related Outcomes
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 93)
DOI
10.1200/JCO.2019.37.8_suppl.93
Abstract #
93
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials.
First Author: Carolyn Moloney
Poster
2022 ASCO Annual Meeting
The effect of the microbiome on immune checkpoint inhibitor toxicity in patients with melanoma.
First Author: Nyelia Williams
Poster
2022 ASCO Annual Meeting
Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Results of an a priori interim analysis of a multicenter phase I trial.
First Author: Shearwood McClelland III
Poster
2018 ASCO Quality Care Symposium
A data driven approach to immunotherapy toxicity management.
First Author: Sadiqa Mahmood